PharmacoEconomics & Outcomes News 792, p27 - 2 Dec 2017
Severity of AD increases resource
use and costs in France
Increased severity of Alzheimer’s disease (AD)
appears to increase resource use and societal costs in
France, according to findings of the Eli Lilly and Co-
funded study published in Value in Health.
This analysis of data from the French cohort of the
observational GERAS study investigated resource use
and societal costs over 18 months in 419 community-
dwelling patients with AD, and the effects of cognitive
decline on patient costs and societal costs. Patients were
enrolled between October 2010 and September 2011.
Cumulative total societal costs over the 18-month
period were significantly higher in patients with
moderately severe or severe AD than in those with mild
or moderate AD (€44 171
vs €24 140 and €34 287,
respectively; p<0.001). Caregiver informal care
accounted for 51%
53% of total societal costs, ranging
from €12 556 in patients with mild AD to €22 704 in
those with moderately severe or severe AD.
Cognitive decline (defined as institutionalisation or
reduction in Mini-Mental State Examination score of
≥3 points) was associated with a 12.5% increase in costs
While caregiver time differed significantly between
AD severity groups (p<0.001), caregiver time per
month increased in all severity groups at 6, 12 and
"Increasing severity of AD dementia in France is
associated with increased total societal and patient
costs, and clinically meaningful cognitive decline is
associated with increased costs," concluded the authors.
"This study confirms the quantity and importance of the
caregiver burden and costs associated with AD . . .
Health and social policies should further focus on
supporting the caregiver," they said.
* 2010 euros
Rapp T, et al. Resource Use and Cost of Alzheimer’s Disease in France: 18-Month
Results from the GERAS Observational Study. Value in Health : 11 Nov 2017.
Available from: URL: https://doi.org/10.1016/j.jval.2017.09.019
PharmacoEconomics & Outcomes News 2 Dec 2017 No. 7921173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved